Terms: = Lymphoma AND TP63, EEC3, 8626, ENSG00000073282, p73H, p63, Q9H3D4, TP73L, p51, OFC8, KET, RHS, B p51B , B p51A , SHFM4, LMS, p73L AND Clinical Outcome
4 results:
1.
Qiu L; Tang G; Li S; Vega F; Lin P; Wang SA; Wang W; Iyer SP; Malpica L; Miranda RN; Konoplev S; Tang Z; Fang H; Medeiros LJ; Xu J
Haematologica; 2023 Jun; 108(6):1604-1615. PubMed ID: 36453104
[TBL] [Abstract] [Full Text] [Related]
2. Systemic ALK-negative anaplastic large cell lymphoma with distinctive myxoid change and DUSP22 rearrangement.
Fratoni S; Trawinska MM; Capalbo A; Bernardini L; Fabbretti M; Martini M; Niscola P; Zhao XF
Virchows Arch; 2022 Dec; 481(6):975-979. PubMed ID: 35879438
[TBL] [Abstract] [Full Text] [Related]
3. The expression and clinical relevance of PD-1, PD-L1, and tp63 in patients with diffuse large B-cell lymphoma.
Fang X; Xiu B; Yang Z; Qiu W; Zhang L; Zhang S; Wu Y; Zhu X; Chen X; Xie S; Yi X; Liang A; Zeng Y
Medicine (Baltimore); 2017 Apr; 96(15):e6398. PubMed ID: 28403071
[TBL] [Abstract] [Full Text] [Related]
4. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.
Parrilla Castellar ER; Jaffe ES; Said JW; Swerdlow SH; Ketterling RP; Knudson RA; Sidhu JS; Hsi ED; Karikehalli S; Jiang L; Vasmatzis G; Gibson SE; Ondrejka S; Nicolae A; Grogg KL; Allmer C; Ristow KM; Wilson WH; Macon WR; Law ME; Cerhan JR; Habermann TM; Ansell SM; Dogan A; Maurer MJ; Feldman AL
Blood; 2014 Aug; 124(9):1473-80. PubMed ID: 24894770
[TBL] [Abstract] [Full Text] [Related]
